Regional therapies for in-transit disease

Paul J. Speicher, Claire H. Meriwether, Douglas Tyler

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In-transit melanoma is an uncommon pattern of recurrence, but presents unique management challenges and opportunities for treatment. The clinical presentation usually involves from 1 to more than 100 small subcutaneous or cutaneous nodules, ranging from submillimeter to multiple centimeters in diameter. Regional chemotherapy techniques are a mainstay of treatment of patients without systemic disease spread. Future applications of regional therapy are likely to involve combination therapy with cytotoxic agents and novel immune modulators. Regional therapy provides distinct opportunities for the treatment of unresectable disease, and offers a unique platform for investigation of novel therapeutics in early-stage clinical trials.

Original languageEnglish (US)
Pages (from-to)309-322
Number of pages14
JournalSurgical Oncology Clinics of North America
Volume24
Issue number2
DOIs
StatePublished - Apr 1 2015

Fingerprint

Therapeutics
Cytotoxins
Melanoma
Clinical Trials
Recurrence
Drug Therapy
Skin

Keywords

  • In-transit melanoma
  • Isolated limb infusion
  • Isolated limb perfusion
  • Regional therapy

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Regional therapies for in-transit disease. / Speicher, Paul J.; Meriwether, Claire H.; Tyler, Douglas.

In: Surgical Oncology Clinics of North America, Vol. 24, No. 2, 01.04.2015, p. 309-322.

Research output: Contribution to journalArticle

Speicher, Paul J. ; Meriwether, Claire H. ; Tyler, Douglas. / Regional therapies for in-transit disease. In: Surgical Oncology Clinics of North America. 2015 ; Vol. 24, No. 2. pp. 309-322.
@article{89bb514a20d5445a93a482bc1fbe5757,
title = "Regional therapies for in-transit disease",
abstract = "In-transit melanoma is an uncommon pattern of recurrence, but presents unique management challenges and opportunities for treatment. The clinical presentation usually involves from 1 to more than 100 small subcutaneous or cutaneous nodules, ranging from submillimeter to multiple centimeters in diameter. Regional chemotherapy techniques are a mainstay of treatment of patients without systemic disease spread. Future applications of regional therapy are likely to involve combination therapy with cytotoxic agents and novel immune modulators. Regional therapy provides distinct opportunities for the treatment of unresectable disease, and offers a unique platform for investigation of novel therapeutics in early-stage clinical trials.",
keywords = "In-transit melanoma, Isolated limb infusion, Isolated limb perfusion, Regional therapy",
author = "Speicher, {Paul J.} and Meriwether, {Claire H.} and Douglas Tyler",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.soc.2014.12.008",
language = "English (US)",
volume = "24",
pages = "309--322",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Regional therapies for in-transit disease

AU - Speicher, Paul J.

AU - Meriwether, Claire H.

AU - Tyler, Douglas

PY - 2015/4/1

Y1 - 2015/4/1

N2 - In-transit melanoma is an uncommon pattern of recurrence, but presents unique management challenges and opportunities for treatment. The clinical presentation usually involves from 1 to more than 100 small subcutaneous or cutaneous nodules, ranging from submillimeter to multiple centimeters in diameter. Regional chemotherapy techniques are a mainstay of treatment of patients without systemic disease spread. Future applications of regional therapy are likely to involve combination therapy with cytotoxic agents and novel immune modulators. Regional therapy provides distinct opportunities for the treatment of unresectable disease, and offers a unique platform for investigation of novel therapeutics in early-stage clinical trials.

AB - In-transit melanoma is an uncommon pattern of recurrence, but presents unique management challenges and opportunities for treatment. The clinical presentation usually involves from 1 to more than 100 small subcutaneous or cutaneous nodules, ranging from submillimeter to multiple centimeters in diameter. Regional chemotherapy techniques are a mainstay of treatment of patients without systemic disease spread. Future applications of regional therapy are likely to involve combination therapy with cytotoxic agents and novel immune modulators. Regional therapy provides distinct opportunities for the treatment of unresectable disease, and offers a unique platform for investigation of novel therapeutics in early-stage clinical trials.

KW - In-transit melanoma

KW - Isolated limb infusion

KW - Isolated limb perfusion

KW - Regional therapy

UR - http://www.scopus.com/inward/record.url?scp=84926124227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926124227&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2014.12.008

DO - 10.1016/j.soc.2014.12.008

M3 - Article

VL - 24

SP - 309

EP - 322

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 2

ER -